NCT06294236View on ClinicalTrials.gov

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 29, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2028

Conditions
Lupus ErythematosusSystemic Lupus ErythematosusSLE (Systemic Lupus)Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGranulomatous PolyangiitisMicroscopic Polyangiitis
Interventions
BIOLOGICAL

SC291

SC291 is an allogeneic CAR T cell therapy

Trial Locations (5)

21287

RECRUITING

Johns Hopkins Hospital, Baltimore

30322

RECRUITING

Emory University, Atlanta

80045

RECRUITING

University of Colorado, Aurora

98122

RECRUITING

Swedish Medical Center, Seattle

02114

RECRUITING

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Sana Biotechnology
All Listed Sponsors
lead

Sana Biotechnology

INDUSTRY

NCT06294236 - Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) | Biotech Hunter | Biotech Hunter